

EXPRESS MAIL CERTIFICATE

Date _____ Label No. _____

I hereby certify that, on the date indicated above, this paper or fee was deposited with the U.S. Postal Service & that it was addressed for delivery to the Assistant Commissioner for Patents, Washington, DC 20231 by "Express Mail Post Office to Addressee" service.

PLEASE CHARGE ANY DEFICIENCY UP TO \$300.00 OR CREDIT ANY EXCESS IN THE FEES DUE WITH THIS DOCUMENT TO OUR DEPOSIT ACCOUNT NO. 04-0100

Name (Print) _____

Signature _____

Customer No.: _____



07278

PATENT TRADEMARK OFFICE

Docket No: 0136/1E154US1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Divisional Application of: Kim, Tae-Yeon; Lee, Ki-Young; Chang, Jin-Soo;
Cho, Sung-Yoo; Hwang, Yu-Kyeong; Choi,
Myeong-Jun

Serial No.: TBA

Art Unit: TBA

Confirmation No.: TBA

Filed: Concurrently Herewith

Examiner:

For: LIPOSOMES COMPRISING PEPTIDE ANTIGENS DERIVED FROM X PROTEIN OF
HEPATITUS B VIRUS

PRELIMINARY AMENDMENT, SUBSTITUTE SEQUENCE LISTING, AND
STATEMENT PURSUANT TO §1.821

Hon. Commissioner of
Patents and Trademarks
Washington, DC 20231

November 20, 2001

Sir:

Prior to examination of the above-identified divisional patent application,
please amend the application as follows.

EXPRESS MAIL CERTIFICATE

11/20/01 62670669601US
Date _____ Label No. _____

I hereby certify that, on the date indicated above, this paper or fee was deposited with the U.S. Postal Service & that it was addressed for delivery to the Assistant Commissioner for Patents and Trademarks, 2900 Crystal Drive, Arlington, VA 22202-3513 by "Express Mail Post Office to Addressee" service.

Name (Print) _____

Signature _____

IN THE SPECIFICATION:

Please insert the enclosed substitute sequence listing for the original sequence listing in the application.

IN THE CLAIMS:

Please cancel claims 1-5, without prejudice.

REMARKS

Claims 1-12 in U.S. Patent Application Serial No. 09/051,006 (referred to herein as "the parent application") were subject to restriction. Claims 1-5 were prosecuted on the merits in the parent application. In the current divisional application, claims 1-5 have been canceled, leaving claims 6-12 pending and at issue.


The specification has been amended to replace the original sequence listing, in the parent application, with a substitute sequence listing (provided concurrently herewith). This substitute sequence listing was filed in the parent application on November 17, 2000. The computer readable form (CRF) of the substitute sequence listing in the instant application is the same as that submitted on November 17, 2000 for the parent application. In accordance with 37 C.F.R. § 1.821(e), please use the CRF filed in the parent application as the CRF for this application. It is understood that the Patent and Trademark Office will make the necessary changes in the application number, filing date, and priority information for

the instant application.

Pursuant to the requirements of 37 C.F.R. §§ 1.821(f) and (g), the undersigned hereby states that the content of the sequence listing information recorded on the CRF, filed in U.S. Patent Application Serial No. 09/051,006 on November 17, 2000, is identical to the substitute sequence listing provided concurrently herewith and does not contain new matter.

Entry of the amendments and paper copy of the substitute sequence listing submitted herewith and use of the CRF filed on November 17, 2000 in the parent application are respectfully requested.

Respectfully submitted,



Neepa Y. Choksi, Ph.D.

Reg. No. 47,488

Agent for Applicants

DARBY & DARBY, P.C.
805 Third Avenue
New York, N.Y. 10022
Phone (212) 527-7700